These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 8030059)
1. CD28-pathway blockade with CTLA4Ig leads to prolongation of small bowel transplant survival in rats. Pescovitz MD; Yang R; Liu Q; Collins MH; Grosfeld JL Transplant Proc; 1994 Jun; 26(3):1618-9. PubMed ID: 8030059 [No Abstract] [Full Text] [Related]
2. Prolongation of rat small bowel allograft survival by CTLA-4 IG. Tarumi K; Yagihashi A; Murakami M; Uede T; Hirata K Transplant Proc; 1998 Sep; 30(6):2596-9. PubMed ID: 9745507 [No Abstract] [Full Text] [Related]
3. Induction and maintenance of tolerance by CTLA-4IG in rat small bowel allografts. Tarumi K; Yagihashi A; Tsuruma T; Koide S; Sasaki K; Hirata K Transplant Proc; 1999; 31(1-2):878-81. PubMed ID: 10083385 [No Abstract] [Full Text] [Related]
4. Review of CTLA4Ig use for allograft immunosuppression. Lin H; Wei RQ; Gordon D; Linsley P; Turka LA; Bolling SF Transplant Proc; 1994 Dec; 26(6):3200-1. PubMed ID: 7998114 [No Abstract] [Full Text] [Related]
5. CD28-B7 T cell costimulatory blockade by CTLA4Ig in sensitized rat recipients: induction of transplantation tolerance in association with depressed cell-mediated and humoral immune responses. Onodera K; Chandraker A; Schaub M; Stadlbauer TH; Korom S; Peach R; Linsley PS; Sayegh MH; Kupiec-Weglinski JW J Immunol; 1997 Aug; 159(4):1711-7. PubMed ID: 9257832 [TBL] [Abstract][Full Text] [Related]
6. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival. Comer RM; King WJ; Ardjomand N; Theoharis S; George AJ; Larkin DF Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1095-103. PubMed ID: 11923251 [TBL] [Abstract][Full Text] [Related]
7. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. Lakkis FG; Konieczny BT; Saleem S; Baddoura FK; Linsley PS; Alexander DZ; Lowry RP; Pearson TC; Larsen CP J Immunol; 1997 Mar; 158(5):2443-8. PubMed ID: 9036995 [TBL] [Abstract][Full Text] [Related]
8. Immunomodulation with intrathymic injection of donor splenocytes followed by CTLA4Ig therapy prolongs small intestinal allograft survival. Greenstein SM; Sun S; Schechner RS; Tellis VA Transplant Proc; 1997; 29(1-2):1065-6. PubMed ID: 9123201 [No Abstract] [Full Text] [Related]
9. Prolongation of skin allograft survival in mice treated with CTLA-4 Ig in combination with rapamycin or cyclosporine. Hale DA; Gottschalk R; Wood ML; Maki T; Monaco AP Transplant Proc; 1996 Dec; 28(6):3270-1. PubMed ID: 8962270 [No Abstract] [Full Text] [Related]
10. Preventing allograft rejection with CTLA4IG: effect of donor-specific transfusion route or timing. Bolling SF; Lin H; Wei RQ; Turka LA J Heart Lung Transplant; 1996 Sep; 15(9):928-35. PubMed ID: 8889989 [TBL] [Abstract][Full Text] [Related]
11. CTLA-4IG treatment induces long-term acceptance of rat small bowel allografts. Tarumi K; Yagihashi A; Tsuruma T; Araya J; Hirata K Transplant Proc; 2000 Nov; 32(7):2028-31. PubMed ID: 11120051 [No Abstract] [Full Text] [Related]
12. Soluble CTLA4Ig modifies acute rejection of rat lung allografts without blocking accumulation of key cytokine transcripts. Matsumura Y; Zuo XJ; Prehn J; Linsley P; Marchevsky A; Kass R; Matloff J; Jordan SC Transplant Proc; 1995 Feb; 27(1):406-8. PubMed ID: 7879040 [No Abstract] [Full Text] [Related]
13. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. Via CS; Rus V; Nguyen P; Linsley P; Gause WC J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665 [TBL] [Abstract][Full Text] [Related]
14. Reversal of CTLA4Ig-mediated tolerance to cardiac allografts by exogenous interleukin-2. Arima T; Rehman A; Flye MW Transplant Proc; 1997; 29(1-2):1305-6. PubMed ID: 9123318 [No Abstract] [Full Text] [Related]
15. Cardiac allograft tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig. Yang Z; Rostami S; Koeberlein B; Barker CF; Naji A Transplantation; 1999 Jun; 67(12):1517-23. PubMed ID: 10401757 [TBL] [Abstract][Full Text] [Related]
16. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. Levisetti MG; Padrid PA; Szot GL; Mittal N; Meehan SM; Wardrip CL; Gray GS; Bruce DS; Thistlethwaite JR; Bluestone JA J Immunol; 1997 Dec; 159(11):5187-91. PubMed ID: 9548454 [TBL] [Abstract][Full Text] [Related]
17. Prolongation of survival of small bowel transplant recipients after treatment with cis-urocanic acid. Gieseler RK; Klemp F; Bredt M; Mentlein R; Kuhn R; von Gaudecker B; Peters JH; Schlemminger R Transplant Proc; 1994 Jun; 26(3):1601-3. PubMed ID: 8030054 [No Abstract] [Full Text] [Related]
18. Importance of the CD28/B7 costimulatory pathway in the development of chronic ductopenic rejection in a new model of orthotopic rat liver allotransplantation. Mark W; Hechenleitner P; Sayegh MH; Hancock WW; Candinas D Transplant Proc; 1997; 29(1-2):1029. PubMed ID: 9123182 [No Abstract] [Full Text] [Related]
19. Prolongation of rat to mouse skin and heart xenograft survival by combined CTLA4Ig and anti-CD4/CD8 antibody. Tu Y; Rehman A; Flye MW Transplant Proc; 1996 Aug; 28(4):2061-2. PubMed ID: 8769156 [No Abstract] [Full Text] [Related]
20. Soluble CTLA4Ig modifies parameters of acute inflammation in rat lung allograft rejection without altering lymphocytic infiltration or transcription of key cytokines. Matsumura Y; Zuo XJ; Prehn J; Linsley PS; Marchevsky A; Kass RM; Matloff JM; Jordan SC Transplantation; 1995 Feb; 59(4):551-8. PubMed ID: 7533346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]